Rocket Pharmaceuticals Reports Q2 2025 Financial Results with $68.9M Net Loss

Rocket Pharmaceuticals, Inc. reported its financial results for the second quarter of 2025, revealing a net loss of $68.9 million, a slight improvement from a net loss of $69.6 million in the same period last year. The company has not generated any revenue, consistent with its ongoing focus on research and development (R&D) for its gene therapy candidates. Total operating expenses for the quarter were $71.1 million, down from $73.7 million in the prior year, primarily due to reduced R&D costs, which decreased to $42.7 million from $46.3 million. General and administrative expenses also fell to $25 million from $27.4 million, reflecting the company's efforts to streamline operations.

In terms of significant changes, Rocket Pharmaceuticals has undergone a strategic corporate reorganization aimed at prioritizing its AAV-based gene therapy platform for cardiovascular diseases. This restructuring, announced in July 2025, included a workforce reduction of approximately 30%, which is expected to lower operating expenses by nearly 25% over the next year. The company incurred restructuring expenses of $3.5 million during the quarter, which were primarily related to severance and termination benefits.

Operationally, Rocket Pharmaceuticals continues to advance its clinical programs, particularly for Danon disease and Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM). The company is currently conducting a pivotal Phase 2 trial for its lead candidate, RP-A501, for Danon disease, although the trial is on clinical hold following serious adverse events reported in participants. The company is actively working with the FDA to address these issues and resume the trial. As of June 30, 2025, Rocket had $271.5 million in cash, cash equivalents, and investments, which it believes will fund operations into the second quarter of 2027.

Looking ahead, Rocket Pharmaceuticals remains focused on its goal of developing potentially curative gene therapies for rare diseases. The company plans to submit a complete response to the FDA regarding the clinical hold on RP-A501 and is also exploring external partnerships to advance its other programs, including those for Fanconi Anemia and Pyruvate Kinase Deficiency. Despite the challenges, the company is committed to its long-term strategy of addressing significant unmet medical needs in the field of genetic disorders.